AVBP (ArriVent BioPharma) Interest Income: $12.21 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AVBP ArriVent BioPharma Inc AVBP
14 GF Score
Price $30.21
! 1 Warning Sign
View Full Analysis

What is ArriVent BioPharma Interest Income?

ArriVent BioPharma AVBP -2.49% 14 Interest Income is $12.21 Mil as of Jun. 2026. GuruFocus rates AVBP with a GF Score™ of 14/100. The stock has 1 warning sign investors should review.

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. ArriVent BioPharma's interest income for the three months ended in Jun. 2026 was $2.80 Mil. Its interest income for the trailing twelve months (TTM) ended in Jun. 2026 was $12.21 Mil.

ArriVent BioPharma Interest Income Historical Data

* Premium members only.

The historical data trend for ArriVent BioPharma's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ArriVent BioPharma Interest Income Chart

ArriVent BioPharma Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Interest Income
0.00 0.00 5.26 13.82 11.23

ArriVent BioPharma Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.22 3.34 3.28 2.79 2.80
AVBP
14GF Score
ArriVent BioPharma Inc AVBP
Interest Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ArriVent BioPharma Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Income →
What does a Interest Income of $12.21 Mil mean?
ArriVent BioPharma (AVBP) has a Interest Income of $12.21 Mil as of Jun. 2026. Interest Income is the amount a company receives on savings accounts and certificates of deposits. View historical data on ArriVent BioPharma and its competitors.
Is ArriVent BioPharma's Interest Income too high?
ArriVent BioPharma's current Interest Income is $12.21 Mil. Overall, ArriVent BioPharma has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does ArriVent BioPharma's Interest Income compare to VIR and SEPN?
ArriVent BioPharma's Interest Income of $12.21 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Income for a Biotechnology company?
A good Interest Income depends on the Biotechnology industry context. However, Interest Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Income mean?
A high Interest Income can signal that a stock is expensive relative to its fundamentals. Interest Income is the amount a company receives on savings accounts and certificates of deposits. View historical data on ArriVent BioPharma and its competitors. ArriVent BioPharma's current Interest Income is $12.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ArriVent BioPharma stock overvalued right now?
ArriVent BioPharma (AVBP) has a current Interest Income of $12.21 Mil. The current Interest Income is $12.21 Mil. ArriVent BioPharma's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Income calculated?
Interest Income is calculated from a company's financial statements. For ArriVent BioPharma (AVBP), the current Interest Income is $12.21 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ArriVent BioPharma Business Description

Address 18 Campus Boulevard, Suite 100, Newtown Square, PA, USA, 19073
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
14GF Score

Get the complete analysis for AVBP

Interest Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$30.21
Price